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Abstract
Background: Chemicals from occupational exposure and components of cigarette smoke can
cause DNA damage in bladder urothelium. Failure to repair DNA damage by DNA repair proteins
may result in mutations leading to genetic instability and the development of bladder cancer.
Immunohistochemistry studies have shown DNA damage signal activation in precancerous bladder
lesions which is lost on progression, suggesting that the damage signalling mechanism acts as a brake
to further tumorigenesis. Single nucleotide polymorphisms (SNPs) in DSB signalling genes may alter
protein function. We hypothesized that SNPs in DSB signalling genes may modulate predisposition
to bladder cancer and influence the effects of environmental exposures.
Methods: We recruited 771 cases and 800 controls (573 hospital-based and 227 population-based
from a previous case-control study) and interviewed them regarding their smoking habits and
occupational history. DNA was extracted from a peripheral blood sample and genotyping of 24
SNPs in MRE11, NBS1, RAD50, H2AX and ATM was undertaken using an allelic discrimination
method (Taqman).
Results: Smoking and occupational dye exposure were strongly associated with bladder cancer
risk. Using logistic regression adjusting for age, sex, smoking and occupational dye exposure, there
was a marginal increase in risk of bladder cancer for an MRE11 3'UTR SNP (rs2155209, adjusted
odds ratio 1.54 95% CI (1.13–2.08, p = 0.01) for individuals homozygous for the rare allele
compared to those carrying the common homozygous or heterozygous genotype). However, in
the hospital-based controls, the genotype distribution for this SNP deviated from Hardy-Weinberg
equilibrium. None of the other SNPs showed an association with bladder cancer and we did not
find any significant interaction between any of these polymorphisms and exposure to smoking or
dye exposure.
Conclusion: Apart from a possible effect for one MRE11 3'UTR SNP, our study does not support
the hypothesis that SNPs in DSB signaling genes modulate predisposition to bladder cancer.
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Background
Tobacco smoke and occupational carcinogens are the
major risk factors for urothelial cell carcinoma of the blad-
der. Products in cigarette smoke cause oxidative DNA
damage which is repaired by base excision repair (BER).
Bulky adducts from metabolism of polycyclic aromatic
hydrocarbons and aromatic amines [1] are repaired by
nucleotide excision repair (NER), although other damage
requires other pathways [2-4]. The most lethal form of
DNA damage is the DNA double strand break (DSB)
which if not repaired can lead to cell death [5]. DSB can
be produced by oxidative lesions in close proximity on
opposing DNA strands or during repair of bulky adducts
causing interstrand cross links which requires a combina-
tion of NER and homologous recombination for their
repair. As only a small proportion of individuals exposed
to environmental carcinogens develop bladder cancer, it
has been suggested that genetic factors are important in
determining the response to carcinogen exposure [6].
Cell-cycle checkpoints and DNA damage repair are two
mechanisms which protect the cell against genetic insta-
bility and mutagenesis [7]. The ATM, H2AX, Chk2 and
p53 proteins are involved in DNA damage recognition
and consequent cell cycle arrest allowing DNA repair or, if
repair fails, cell death.
Other proteins involved in signalling of DSB damage
include the MRE11-RAD50-NBS1 (MRN) complex which
has been shown to act both upstream of ATM, with NBS1
responsible for the activation of ATM, and downstream of
ATM, leading to the activation of DSB repair by homolo-
gous recombination or non-homologous end joining.
DSB are also formed during mitosis when replication
forks arrest and the MRN complex has also been impli-
cated in the signalling pathway for the detection of these
collapsed replication forks [8]. The MRN complex is
involved in G1/S cell cycle checkpoint activation and can
phosphorylate Chk2 [9], while Chk1, involved in the G2/
M checkpoint, is phosphorylated by ATM or ATR in
response to DNA damage [10,11]. Telomere integrity is
important for genomic stability, and cells deficient in
ATM or MRE11 have shortened telomeres [12]. ATM and
the MRN complex are thought to be involved in telomere
stabilization by preventing fusion between the free ends
of the chromosomes [13]. H2AX is rapidly phosphor-
ylated at the sites of DSB and is important for the recruit-
ment of repair proteins [14]. Interestingly, MRE11, ATM
and H2AX are located on the long arm of chromosome
11.  MRE11  is located at 11q21, ATM  at 11q22.3 and
H2AX at 11q23.2-23.3.
Compared to the small proportion of cancers associated
with high penetrance mutations, the majority of cancers
are thought to be caused by a combination of low pene-
trance genes and environmental factors. Single nucleotide
polymorphisms (SNPs) are found in numerous DNA
repair genes in the general population. Individuals vary
markedly in their intrinsic DNA repair capacity and there
is evidence that decreased repair capacity is associated
with increased cancer risk [6,15]. SNPs in the DNA repair
signalling genes may account for some of this variation
[16].
A number of studies have looked at variants in genes in
the various DNA repair pathways, mainly focusing on the
BER and NER pathways, and also cell cycle genes [6,17-
20,23-25] and association with bladder cancer. No single
variant has been conclusively associated with bladder can-
cer risk. In a large case-control study conducted by Garcia-
Closas et al [17], variant genotypes of SNPs within the
NER pathway genes were found to be associated with
small increases in bladder cancer risk (with odds ratios
ranging between 1.2 and 1.4). Wu et al [6] studied 44
SNPs in 33 genes associated with DNA repair and cell
cycle control. They found that only three of the SNPs, XPD
Asp312Asn, RAG1 Lys820Arg, and a TP53 intronic SNP
exhibited statistically significant effects, but that increas-
ing numbers of potentially high risk alleles within the
NER pathway or the combined DNA repair and cell cycle
control pathways had a significant effect on increased
bladder cancer risk. We have previously shown an associ-
ation between three SNPs in XPC, one of the key NER
genes, and bladder cancer risk [18]. Sanyal et al [19] stud-
ied a number of SNPs in DNA repair genes in 327 bladder
cancer patients including one in NBS1 (Glu185Gln), but
this was not found to be significantly associated with
bladder cancer risk. Figueroa et al recently found no asso-
ciation with four NBS1 variants and bladder cancer risk
[26]. However, variants in other components of the DSB
signalling pathway have not yet been studied in bladder
cancer.
Large case-control studies in breast cancer have not shown
any association between variants within the ATM  and
NBS1 genes and disease risk [27-32], although ATM vari-
ants have been weakly associated with an increased risk of
lung cancer in two studies [33,34], and NBS1 Glu185Gln
has been associated with increased lung cancer risk in a
Chinese study [35], but not in a Norwegian study [36].
We hypothesized that potentially functional SNPs within
the  MRE11, RAD50, NBS1, ATM and  H2AX  genes, by
affecting DSB signalling and genomic stability may mod-
ulate predisposition to bladder cancer, and that these
SNPs may modify the bladder cancer risk associated with
smoking and occupational exposures.BMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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Methods
Cases and Controls Selection and Recruitment
This has been described previously [20]. Ethical approval
was obtained from Leeds (East) Local Research Ethics
Committee (LREC). Patients with histologically proven
bladder cancer were recruited at the Pyrah Department of
Urology, St James's University Hospital, Leeds, (SJUH)
from August 2002 to March 2006.
Five hundred and seventy-three control individuals were
recruited from the ophthalmology and ear, nose and
throat (ENT) departments, SJUH (hospital-based con-
trols). Informed consent was obtained from each subject.
Attempts were made to frequency match the control pop-
ulation for sex as bladder cancer is more prevalent in
males. Individuals had no previous history of bladder
cancer or symptoms of haematuria. A second group of 227
controls were used from a previous case-control study
undertaken by the Genetic Epidemiology Laboratory, CR-
UK Clinical Centre, Leeds (community controls) [37].
Information regarding smoking habits, occupation (expo-
sure to occupational carcinogens) and ethnicity (Cauca-
sian or non-Caucasian) were obtained from direct
interviews with both case and control subjects.
DNA Extraction and Storage
Five millilitre blood samples were obtained from cases
and controls. All blood samples were sent to the Regional
Genetics Laboratory, SJUH, for DNA extraction using a
salt precipitation method and stored at -20°C until
required as previously described [20].
Selection of SNPs for MRE11, NBS1, RAD50, ATM and 
H2AX
A list of SNPs for MRE11, NBS1, RAD50, ATM and H2AX
were obtained from the public domain of the Environ-
mental Genome Project (EGP) via the National Center for
Biotechnology Information (NCBI) http://
www.ncbi.nlm.nih.gov/SNP/index.html and GeneSNP
from the University of Utah http://
www.genome.utah.edu/genesnps. Non-synonymous
exonic SNPs, SNPs at known splice sites within 50 base
pairs downstream and upstream of the exon, and 5' and 3'
UTR SNPs with an allele frequency >3% were chosen.
Although 30 SNPs were selected, six could not be geno-
typed using the TaqMan method (Applied Biosystems,
Foster City, CA). A total of 24 SNPs were genotyped.
Genotyping
The DNA samples were sent for high throughput genotyp-
ing to the CR-UK Genotyping Facility in Oxford using the
TaqMan method[20]. To ensure quality control, the DNA
was viewed on an agarose gel to check molecular weight
and look for fragmentation or degradation. All DNA was
quantified using pico green and then normalised to 50 ng/
ul before being diluted to 5 ng/ul. A PCR reaction for a β-
Actin fragment (approx 500 bp) was performed to check
the quality of DNA. On the TaqMan plates, non-template
controls were included (blanks) to indicate the back-
ground fluorescence and, hence, illustrate positives from
failures. Commercially purchased DNA was included on
all plates (positive controls) to ensure that each plate had
amplified successfully. Five percent of samples were blind
duplicates so that concordance between genotype calls
could be assessed. Genotyping calls were checked by two
people independently.
Confirmatory sequencing of MRE11 rs2155209
Confirmatory sequencing was performed for the MRE11
variant rs2155209. Thirty two wild type, 31 heterozygous
and 32 variant homozygous genotyped samples were
identified across the 96-well plates and the samples
sequenced using a Big Dye Terminator v1.1 Cycle
Sequencing kit as per the manufacturer's instructions.
Briefly, the region containing the variant was amplified by
PCR reaction in a thermal cycler using the following
primer sequences: Forward: 5' GGCTAATTATGGTAT-
TACTGCATAGG 3', Reverse: 5' TCAAGCATTTAGGAAT-
GTGACC 3'. PCR products were cleaned up with ExoSap-
IT (GE Healthcare, Little Chalfont, UK) and then directly
sequenced in a reaction mix containing v1.1 BigDye Ter-
minator reaction mix (Applied Biosystems, Warrington,
UK). DNA sequencing products were cleaned up by etha-
nol precipitation, resuspended in Hi-Di formamide
(Applied Biosystems, Warrington, UK) and analysed on
an Applied Biosystems 3730 × l DNA analyser. Sequenc-
ing data was analysed using Mutation Surveyor software
(Softgenetics, Pennsylvania, USA).
Statistical Analysis
All statistical analysis was undertaken using STATA9 soft-
ware (StataCorp, Texas, USA). The genotype frequency of
each SNP was tested for deviation from Hardy-Weinberg
equilibrium amongst the controls. This was done by com-
paring the observed genotype frequencies with the
expected frequencies using a Chi-squared test. Minor
allele frequencies for each SNP were compared to those in
the NCBI database. Pairwise Lewontin's D' was calculated
to determine linkage disequilibrium between the SNPs.
Pearson's Chi-squared tests were used to compare sex and
ethnicity between cases and controls and a Two-tailed T-
test was used for age at diagnosis for cases and age at
blood sampling for the controls. Smoking status was cate-
gorized as ever versus never smoked. Pack years of smok-
ing was also calculated (number of cigarettes per day/20)
× number of years smoked)). Exposure to six occupational
hazards (rubber, plastics, labs, printing, dyes, diesel) were
analysed as ever versus never and the total number ofBMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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exposures was calculated from these six occupational haz-
ards. Odds ratios and 95% confidence intervals were esti-
mated for each occupational hazard and smoking status
(ever versus never) separately on bladder cancer risk.
Smoking status (ever versus never) and occupational dye
exposure (ever versus never) were then entered into a
logistic regression model together to assess the independ-
ence of these two risk factors on bladder cancer. The anal-
yses for smoking status (ever versus never) and dye
exposure (ever versus never) were then repeated, stratified
by genotype group for each SNP to assess potential differ-
ential effects of smoking and dye exposure separately by
genotype group. Likelihood ratio tests were carried out to
test for gene-exposure interactions by comparing a model
including an interaction term to a model including only
the main effects.
Odds ratios and 95% confidence intervals were estimated
to assess the effect of each SNP on bladder cancer risk
unadjusted and then adjusted for age, sex, smoking (ever
versus never) and dye exposure (ever versus never) in mul-
tivariable logistic regression. Simhap (McCaskie, 2004)
[21] was used to calculate haplotype odds ratios and 95%
confidence intervals from logistic regression, after using
estimation maximisation techniques to infer haplotypes
for the unphased genotype data.
In order to determine if multiple SNPs within the pathway
may have an additive effect on bladder cancer risk, a com-
bined analysis of four SNPs, one from each of NBS1,
MRE11, ATM and H2AX was undertaken. A SNP from
each gene was chosen by picking the SNP with the highest
minor allele frequency which was in strong linkage dise-
quilibrium with the other SNPs within the gene. The
number of rare alleles was calculated and categorized into
three groups; <3, 3–5, >5. Odds ratios and 95% confi-
dence intervals were calculated for having 3–5 or >5 rare
alleles as compared to having <3 alleles (the reference
group) in logistic regression adjusted for age, sex, smoking
status and dye exposure.
EpiInfo version 3.3.2 (Centers for Disease Control and
Prevention, USA) was used to calculate the power for the
case-control study. The study was powered (80%) to
detect an odds ratio (OR) of 1.5 with a minor allele fre-
quency of 0.3 or an OR of 1.8 with a minor allele fre-
quency of 0.2 significant at the 1% level. Although a large
case-control cohort was studied, the study was underpow-
ered to detect effects for SNPs with low minor allele fre-
quencies.
As a guide to interpretation of results in the context of
multiple testing, false positive report probability (FPRP)
was calculated according to Wacholder et al [22]. The
FPRP is the probability that there is no association given a
statistically significant finding and is based on the
observed significance level, the power to detect an associ-
ation at that level and the prior probability that the asso-
ciation is real, used to reflect the strength of the prior
hypothesis and preceding data. Given the limited number
of previous studies based on our SNP set, a moderate prior
probability of 1% was used.
Results
Study Subjects
There was no difference in sex or age distribution between
the case and control populations (Table 1). The majority
of subjects were Caucasian with no difference in ethnicity
between cases and controls. Histologically 756 patients
(98.0%) had transitional cell carcinomas, nine (1.2%)
had pure squamous cell carcinomas, three (0.4%) had
pure adenocarcinomas and three patients (0.4%) had
neuroendocrine, sarcomatoid and leiomyosarcoma
respectively. The distribution of stage and grade are
shown in Table 1.
Effects of Environmental Risk Factors
Smoking was found to be associated with an increased
risk of bladder cancer (OR = 1.78, 95%CI (1.42–2.24) for
ever versus never smoked, Table 1). When the data were
analysed quantitatively using packyears, a dose response
was found with a 1% increase in bladder cancer risk for
each packyear smoked (p < 0.0001). Those subjects
exposed to occupational carcinogens had an increased
bladder cancer risk, the association being strongest for dye
exposure (OR = 2.20, 95%CI (1.37–3.52)). When the
number of exposures was analysed, there was an esti-
mated 27% increase in bladder cancer risk for each addi-
tional occupational exposure (95%CI 1.06–1.51, Table
1). Smoking status (ever versus never) and dye exposure
(ever versus never) were both entered into a multivariable
model and were found to be independent risk factors for
bladder cancer; the adjusted OR for smoking was 1.75
(95%CI 1.38–2.22) and the adjusted OR for dye exposure
was 2.15 (95%CI 1.33–3.48) (data not shown).
Genotyping
All SNPs were successfully genotyped in more than 95%
of samples (see Additional file 1). The 5% of samples gen-
otyped in duplicate showed 99.99% concordance. The
combined hospital-based and community control geno-
type distribution did not deviate from Hardy-Weinberg
equilibrium for any of the SNPs. However in analysis
restricted to the community control group, the genotype
distribution for rs643788 deviated from Hardy-Weinberg
equilibrium (p = 0.04) and in analysis restricted to the
hospital-based control group, the genotype distribution
for rs2155209 deviated from Hardy-Weinberg equilib-
rium (p = 0.01). The minor allele frequencies were con-
sistent with those in the public domain (Table 2). TheseBMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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frequencies were obtained at the start of the study when
the frequencies in the dbSNP database described pooled
ethnicity. Where the observed minor allele frequency
deviated from those in the public domain, this was due to
the predominant non-European influence on allele fre-
quencies within the NCBI and Utah databases for that par-
ticular SNP. SNPs within each gene were found to be in
strong linkage disequilibrium (LD) (Table 3 and Table 4).
Only one of the 24 SNPs, the MRE11 3'UTR SNP
rs2155209 showed an association with bladder cancer
risk (Table 2). In analyses adjusting for age, sex, smoking
and occupational dye exposure, individuals homozygous
for the rare allele of rs2155209 had an OR of 1.54 (95%
CI 1.13–2.08, p = 0.01) when compared to those carrying
the common homozygous genotype or heterozygous gen-
otype. In analysis restricted to the Caucasian subjects the
results were very similar (adjusted OR = 1.47, 95%CI
(1.08–2.00) p = 0.02). However, the rs2155209 genotype
distribution deviated from Hardy-Weinberg equilibrium
in the hospital-based control group and when the geno-
type distribution of the community controls was com-
pared to the cases, there was no evidence of an effect
(adjusted OR = 0.96, 95% CI (0.61–1.49) for the rare
homozygotes compared to the grouped common
homozygotes/heterozygotes). The false positive report
probability (FPRP) for the observed association was 53%,
so the finding is approximately equally likely to be a true
or a false finding. No haplotypes were found to increase
bladder cancer risk in any gene (Table 5).
Table 1: The distribution of sex, age and ethnicity amongst 771 cases and 800 controls and Odds ratios (OR) and 95% Confidence 
Intervals (95%CI) from nine unadjusted logistic regression models for the effect of smoking and occupational exposures on bladder 
cancer risk
Characteristic Categories Statistic Number of Cases (%) Number of Controls 
(%)
OR (95% Cl) p-value
Stage of bladder tumour N (%)
Superficial 322 (41.8)
Carcinoma in situ 14 (1.8)
T1/2 298 (38.7)
T3/4 66 (8.5)
Unknown 71 (9.2)
Grade of bladder tumour N (%)
G1 87 (11.3)
G2 313 (40.6)
G3 325 (42.1)
Unknown 46 (6.0)
Sex Male N (%) 544 (70.9) 527 (67.3) 0.12*
Female 223 (29.1) 256 (32.7)
Age Mean (range) 73.2 (30.1–100.7) 73.1 (28.1–99.7) 0.88**
Ethnicity Caucasian N (%) 759 (98.6) 783 (97.9)
Non-caucasian 11 (1.4) 17 (2.1) 0.30*
Smoking Never N (%) 163 (21.3) 254 (32.5) 1.0
Ever 603 (78.7) 528 (67.5) 1.78 (1.42–2.24) <0.0001
Pack year Median (range) 21.0 (0–177.9) 11.3 (0–184.0) 1.01 (1.00–1.01) <0.0001§
Rubber Ever vs never N (%) 10 (1.3) 5 (0.6) 2.05 (0.70–6.02) 0.18
Plastics Ever vs never N (%) 21 (2.7) 11 (1.4) 1.97 (0.94–4.11) 0.06
Labs Ever vs never N (%) 23 (3.0) 14 (1.8) 1.69 (0.86–3.31) 0.11
Printing Ever vs never N (%) 45 (5.9) 45 (5.8) 1.01 (0.67–1.56) 0.93
Dyes Ever vs never N (%) 56 (7.3) 27 (3.5) 2.20 (1.37–3.52) 0.001
Diesel Ever vs never N (%) 88 (11.5) 84 (10.8) 1.07 (0.78–1.42) 0.66
Number of 0 N (%) 569 (74.3) 620 (79.6) 1.0
occupational 1 165 (21.5) 139 (17.8) 1.27 (1.06–1.51) 0.009§
exposures 2 24 (3.1) 14 (1.8)
3 6 (0.8) 5 (0.6)
4 0 (0) 1 (0.1)
50  ( 0 ) 0  ( 0 )
6 2 (0.3) 0 (0)
* Pearson's Chi-squared test
** Two-tailed T-test
§ P-value for linear trend
Missing sex for 4 patients, ethnicity for 1 patient and smoking exposures for 5 patientBMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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Table 2: Odds ratios and 95% Confidence Intervals for the effect of each SNP on bladder cancer risk from unadjusted and adjusted 
logistic regression models (adjusted for age, sex, smoking status and exposure to dyes)
SNP rs 
number, 
function, 
allele 
substitution
Control 
minor allele 
frequency 
(published)*
No of rare 
alleles
Number of 
Cases
Number of 
Controls
Unadjusted 
OR (95% CI)
p value for 
un-adjusted 
OR
Adjusted 
OR (95% CI)
p value for 
adjusted OR
NBS1
rs1448 3'UTR 
A/G
0.06 (0.189) 0 670 (89.0) 695 (89.1) 1 1
1 81 (10.8) 85 (10.9) 0.99 
(0.71–1.36)
0.94 0.98 
(0.71–1.37)
0.91
2 2 (0.3) 0 (0) NDa ND
rs9995 3'UTR 
A/G
0.31 (0.36) 0 334 (44.2) 373 (47.5) 1 1
1 347 (46.0) 332 (42.3) 1.17 
(0.95–1.44)
0.15 1.16 
(0.94–1.44)
0.17
2 74 (9.8) 80 (10.2) 1.03 
(0.73–1.40)
0.86 1.04 
(0.73–1.48)
0.85
rs13312986 
3'UTR A/G
0.01 (0.067) 0 717 (95.1) 765 (97.3) 1 1
1 36 (4.8) 21 (2.7) 1.83 
(1.06–3.16)
0.02 1.72 
(0.99–3.02)
0.06
2 1 (0.1) 0 (0) ND ND
rs1063054 
3'UTR T/G
0.31 (0.33) 0 329 (44.3) 374 (47.8) 1 1
1 340 (45.8) 330 (42.2) 1.17 
(0.95–1.45)
0.14 1.15 
(0.93–1.44)
0.18
2 74 (10.0) 79 (10.1) 1.06 
(0.75–1.51)
0.73 1.06 
(0.75–1.53)
0.71
rs13312981 
3'UTR A/G
0.006 (0.034) 0 751 (99.6) 771 (98.7) 1 1
1 3 (0.4) 10 (1.3) 0.31 
(0.08–1.12)
0.05 0.35 
(0.09–1.27)
0.11
2 0 (0) 0 (0) ND ND
rs2735383 
3'UTR G/C
0.32 (0.335) 0 328 (44.6) 363 (47.1) 1 1
1 336 (45.7) 326 (42.3) 1.14 
(0.92–1.41)
0.23 1.14 
(0.92–1.41)
0.27
2 72 (9.8) 81 (10.5) 0.98 
(0.69–1.40)
0.93 0.98 
(0.69–1.40)
0.93
rs1063053 
3'UTR C/T
0.32 (0.312) 0 331 (44.4) 370 (47.2) 1 1
1 340 (45.6) 334 (42.6) 1.14 
(0.92–1.41)
0.23 1.13 
(0.92–1.41)
0.25
2 74 (9.9) 80 (10.2) 1.03 
(0.72–1.47)
0.85 1.04 
(0.73–1.49)
0.83
rs1805794 
NS G/C 
Glu185Gln
0.31 (0.306) 0 347 (46.4) 375 (47.6) 1 1
1 332 (44.4) 330 (41.9) 1.08 
(0.88–1.34)
0.44 1.06 
(0.86–1.32)
0.57
2 69 (9.2) 83 (10.5) 0.89 
(0.63–1.28)
0.55 0.93 
(0.65–1.33)
0.68
rs769420 NS 
G/A 
Leu266Pro
0.001 (0.033) 0 756 (99.7) 782 (99.7) 1 1
1 2 (0.3) 2 (0.3) 1.03 
(0.15–7.36)
0.97 1.04 
(0.14–7.54)
0.97
2 0 (0) 0 (0) ND ND
MRE11BMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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rs2155209 
3'UTR A/G
0.34 (0.27) 0 306 (41.0) 324 (41.9) 1 1
1 325 (43.6) 367 (47.5) 0.93 
(0.76–1.16)
0.50 0.90 
(0.72–1.12)
0.34
2 115 (15.4) 82 (10.6) 1.48 
(1.07–2.05)
0.02 1.39 
(1.00–1.94)
0.05
2v(0+1) 1.54 (1.13–
2.08) b
0.01
rs1061956 
3'UTR A/G
0.008 (0.04) 0 747 (98.8) 774 (98.5) 1 1
1 9 (1.2) 12 (1.5) 0.78 
(0.33–1.86)
0.57 0.71 
(0.29–1.72)
0.45
2 0 (0) 0 (0) ND ND
rs641936 
5'UTR A/G
0.31 (0.45) 0 352 (47.9) 364 (47.4) 1 1
1 308 (41.9) 329 (42.8) 0.97 
(0.78–1.20)
0.77 0.98 
(0.79–1.21)
0.85
2 75 (10.2) 75 (9.8) 1.03 
(0.73–1.47)
0.85 1.16 
(0.81–1.67)
0.43
rs1805365 
5'UTR T/C
0.008 (0.048) 0 727 (98.8) 763 (98.3) 1 1
1 9 (1.2) 13 (1.7) 0.73 
(0.31–1.71)
0.47 0.66 
(0.27–1.58)
0.35
2 0 (0) 0 (0) ND ND
rs535801 SS 
C/T
0.29 (0.417) 0 381 (52.1) 393 (51.2) 1 1
1 292 (40.0) 307 (40.0) 0.98 
(0.79–1.21)
0.86 1.00 
(0.81–1.25)
0.97
2 58 (7.9) 68 (8.9) 0.88 
(0.60–1.28)
0.51 1.00 
(0.68–1.49)
0.98
rs497763 
3'UTR G/A
0.42 (0.488) 0 259 (34.5) 278 (35.4) 1 1
1 373 (49.7) 363 (46.2) 1.10 
(0.88–1.38)
0.39 1.13 
(0.90–1.42)
0.35
2 119 (15.9) 145 (18.5) 0.88 
(0.66–1.18)
0.40 0.97 
(0.72–1.32)
0.85
ATM
rs2234997 
NS A/T 
Glu126Asp
0.001 (0.001) 0 744 (99.5) 784 (99.9) 1 1
1 4 (0.5) 1 (0.1) 4.22 
(0.47–37.8)
0.15 4.20 
(0.46–38.1)
0.20
2 0 (0) 0 (0) ND ND
rs3092856 
NS C/T 
Tyr32His
0.001 (0.035) 0 753 (100) 788 (99.8) 1 1
1 0 (0) 2 (0.3) ND ND
2 0 (0) 0 (0) ND ND
rs582157 
3'UTR T/A
0.46 (0.438) 0 215 (28.7) 220 (28.2) 1 1
1 380 (50.8) 400 (51.3) 0.97 
(0.77–1.23)
0.81 0.98 
(0.77–1.24)
0.85
2 153 (20.5) 160 (20.5) 0.98 
(0.73–1.31)
0.88 1.00 
(0.75–1.35)
0.96
rs1263936 
3'UTR G/A
0.45 (0.375) 0 225 (30.2) 229 (29.5) 1 1
1 381 (51.1) 391 (50.3) 0.99 
(0.79–1.25)
0.94 0.99 
(0.78–1.25)
0.90
2 140 (18.8) 157 (20.2) 0.91 
(0.68–1.22)
0.52 0.94 
(0.70–1.27)
0.70
rs609261 
5'UTR A/G
0.46 (0.49) 0 215 (28.6) 221 (28.3) 1 1
Table 2: Odds ratios and 95% Confidence Intervals for the effect of each SNP on bladder cancer risk from unadjusted and adjusted 
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1 384 (51.1) 396 (50.6) 1.00 
(0.79–1.26)
0.98 1.00 
(0.79–1.27)
0.98
2 152 (20.2) 165 (21.1) 0.95 
(0.71–1.26)
0.71 0.98 
(0.73–1.31)
0.88
RAD50
rs1047382 NS 
A/G Ala558Val
0.001 (0.095) 0 755 (100) 789 (99.9) 1 1
1 0 (0) 1 (0.1) ND ND
2 0 (0) 0 (0) ND ND
H2AX
rs643788 3'UTR 
A/G
0.42 (0.491) 0 235 (31.8) 272 (35.1) 1 1
1 368 (49.8) 354 (45.7) 1.20 
(0.96–1.51)
0.11 1.20 
(0.95–1.51)
0.13
2 136 (18.4) 149 (19.2) 1.06 
(0.80–1.41)
0.71 1.03 
(0.76–1.38)
0.86
rs8551 3'UTR 
G/A
0.45 (0.485) 0 236 (31.5) 277 (35.4) 1 1
1 369 (49.2) 371 (47.4) 1.15 
(0.93–1.46)
0.18 1.16 
(0.92–1.46)
0.20
2 145 (19.3) 134 (17.1) 1.27 
(0.95–1.70)
0.11 1.25 
(0.93–1.69)
0.14
rs7350 INT G/A 0.36 (0.413) 0 286 (38.4) 325 (41.8) 1 1
1 353 (47.5) 342 (44.0) 1.17 
(0.94–1.46)
0.15 1.20 
(0.96–1.50)
0.11
2 105 (14.1) 111(14.3) 1.07 
(0.79–1.47)
0.65 1.03 
(0.75–1.41)
0.87
a) ND – Not determined because of zero count for case or control population.
b) The OR was calculated by comparing the rare homozygotes with the combined common homozygotes and heterozygotes as the bladder cancer 
risk appeared to be confined to the rare homozygotes.
* Allele frequencies obtained from the Environmental Genome Project (EGP) via the National Center for Biotechnology Information (NCBI) at 
start of study (ie. pooled ethnicity)
Table 2: Odds ratios and 95% Confidence Intervals for the effect of each SNP on bladder cancer risk from unadjusted and adjusted 
logistic regression models (adjusted for age, sex, smoking status and exposure to dyes) (Continued)
Gene-environment interactions
The effects of smoking status and dye exposure on bladder
cancer risk stratified by genotype are shown in Additional
files 2 and 3 respectively. There was no suggestion of inter-
action between smoking status or dye exposure and any
variant.
Analysis of multiple variants in the same pathway
The number of rare alleles was calculated from four SNPs
(rs2735383, rs497763, rs609261 and rs8551) to repre-
sent the maximum variation within the subject popula-
tion. No association with bladder cancer risk was found
for individuals with increasing numbers of rare alleles
when adjusting for age, sex, smoking status and dye expo-
sure (see Additional file 4). When the analysis was
Table 3: Linkage disequilbrium as determined using Lewontins D' between SNPs in MRE11, ATM and H2AX genes.
MRE11 ATM H2AX
rs 2155209 rs 641936 rs 535801 rs 497763 rs 582157 rs 1263936 rs 609261 rs 643788 rs 8551 rs 7350
MRE11 rs 2155209 0.36 1
rs 641936 0.99 0.31
rs 535801 0.87 0.92 0.28
rs 497763 0.90 0.88 1.0 0.41
ATM rs 582157 0 0 0 0.01 0.46
rs 1263936 0.01 0.02 0 0 0.91 0.45
rs 609261 0.01 0.01 0.01 0.01 0.90 0.97 0.46
H2AX rs 643788 0.01 0.05 0.04 0.01 0.01 0.02 0.02 0.43
rs 8551 0.01 0.05 0.05 0.01 0.01 0.02 0.02 1.0 0.42
rs 7350 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.98 0.94 0.37
(1) Numbers in bold along the diagonal of the tables represent the minor allele frequencyBMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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Table 4: Linkage disequilbrium as determined using Lewontins D' between SNPs in the NBS1 gene.
NBS1
rs1448 rs9995 rs13312986 rs1063054 rs2735383 rs1063053 rs1805794
NBS1 rs1448 0.06 1
rs9995 1.0 0.32
rs13312986 0.98 0.94 0.02
rs1063054 1.0 0.99 0.92 0.32
rs2735383 1.0 0.99 0.95 0.99 0.32
rs1063053 1.0 0.98 0.95 0.99 0.99 0.32
rs1805794 0.25 0.70 0.92 0.71 0.71 0.71 0.31
SNPs with a minor allele frequency less than 1% were excluded
(1) Numbers in bold along the diagonal of the tables represent the minor allele frequency
repeated using the SNP rs2155209, there was still no effect
of number of rare alleles with bladder cancer risk.
Confirmatory sequencing of MRE11 variant rs2155209
Sixty-seven of the 95 selected samples were successfully
genotyped. The failure of the remaining 29 was attributed
to the DNA quality and quantity. The wildtype genotype
was confirmed in 23 samples and the homozygous variant
in 20. Of 23 sequenced samples found to be heterozygous
on Taqman genotyping, 20 were definitely confirmed as
heterozygous on genotyping and in a further three the C
allele was a very minor species.
Discussion
To our knowledge, this is the first epidemiological study
to focus on the DSB signalling pathway in bladder cancer,
evaluating the effect of potentially functional variants in
ATM, MRE11, NBS1, RAD50 and H2AX on bladder cancer
risk.
We found an association for the MRE11 SNP rs2155209
with bladder cancer risk. If a Bonferroni correction had
been used to account for multiple testing in this study, no
SNP would be significantly associated with bladder can-
cer. However, a Bonferroni correction is likely to be an
overcorrection as Bonferroni assumes independence
between multiple tests. We calculated the false positive
report probability for the observed association as an alter-
native method of correcting for multiple testing and
found the result to be approximately equally likely to be a
true or a false finding. The lack of Hardy-Weinberg equi-
librium amongst the hospital-based control group for this
SNP may provide some evidence that this result is a false
positive, considering that no effect of rs2155209 was seen
when comparing the community controls with the cases.
Therefore this result requires validation in a further
cohort.
In line with the current literature [38-41] we found a
strong association between bladder cancer risk and both
smoking and dye exposure, and a weaker association with
plastics manufacturing. However, there was no modifica-
tion of these effects when stratifying by SNP genotype.
As MRE11, NBS1, RAD50, ATM, and H2AX interact with
each other to facilitate DSB damage signalling, we hypoth-
esized that there may be a gene dosage effect in our study,
with subjects with increasing numbers of high risk alleles
having an increased risk of bladder cancer. However, there
was no difference found between the case and control
populations with adjusted odds ratios of ~1.0 and tight
confidence intervals.
The case and control populations had similar age and sex
distributions with no significant difference in ethnicity.
Quality control was stringent in the study with a low pro-
portion of undetermined samples and high concordance
among the duplicate samples. The sequencing of MRE11
variant rs2155209 confirmed the Taqman genotyping
results. One of the strengths of this study is the detailed
information on occupational history in a mainly Cauca-
sian population based in West Yorkshire which allows the
investigation of gene-environment interactions. Despite
this, it is likely that the study was underpowered to detect
such interactions. There is always an inherent recall bias in
this sort of questionnaire-based study, with the possibility
that case subjects are more likely to remember smoking
dose and any hazardous exposures. Occupational expo-
sure was difficult to quantify from the interviews.
The MRE11 variant associated with bladder cancer was
located in the 3'UTR of the gene. The 3'UTR has been
implicated in regulation of transcription and mRNA sta-
bility [42]. Variants in this region of a gene may have func-
tional significance by affecting transcription and leading
to reduced or abnormal protein expression. Alternatively,
the variant may be in linkage disequilibrium with a func-
tional variant nearby.
To our knowledge, there have been no previous studies
investigating variants in ATM, MRE11, RAD50 or H2AX
and bladder cancer risk. However, Mongiat-Artus et alBMC Medical Genetics 2008, 9:69 http://www.biomedcentral.com/1471-2350/9/69
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Table 5: Haplotype analysis for association with bladder cancer 
risk
Gene Haplotype (%)* OR (95% CI) p-value
NBS1
AAATGCG (59.3) 1.0
AGAGCTC (25.5) 1.06 (0.90–1.26) 0.49
AGAGCTG (6.4) 1.13 (0.86–1.49) 0.44
Rare<5% (8.8) 1.04 (0.88–1.22) 0.55
MRE11
AACA (34.2) 1.0
AACG (26.3) 0.88 (0.68–1.13) 0.32
AGTA (22.2) 0.83 (0.68–1.01) 0.07
GACG (10.2) 0.92 (0.76–1.11) 0.38
Rare<5% (7.1) 0.90 (0.73–1.10) 0.34
ATM
TGG (52.0) 1.0
AAA (43.3) 0.97 (0.84–1.13) 0.73
Rare<5% (4.7) 1.01 (0.87–1.17) 0.77
H2AX
AGG (55.9) 1.0
GAA (35.5) 1.11 (0.95–1.29) 0.20
GAG (6.8) 1.13 (0.87–1.46) 0.44
Rare<5% (1.8) 1.02 (0.86–1.21) 0.61
SNPs with a minor allele frequency less than 1% were excluded
NBS1 SNPs were, in order, rs1448 (A/G) rs9995 (A/G) rs13312986 
(A/G) rs1063054 (T/G) rs2735383 (G/C) rs1063053 (C/T) rs1805794 
(G/C)
MRE11 SNPs were, in order, rs2155209 (A/G) rs641936 (A/G) 
rs535801 (C/T) rs497763 (G/A)
ATM SNPs were, in order, rs582157 (T/A) rs1263936 (G/A) 
rs609261 (A/G)
H2AX SNPs were, in order, rs643788 (A/G) rs8551 (G/A) rs7350 (G/
A)
* Percentage frequencies of haplotype(s) are indicated in brackets
have reported mutations of MRE11 or RAD50 in upper
tract urothelial tumours, although numbers are small
(four of 58 tumours) [43]. The MRE11 3'UTR variant has
not yet been investigated for possible cellular functional
effects. In vitro studies may provide a mechanistic explana-
tion for the increase in bladder cancer risk by determining
if the variant leads to reduced transcription or instability
of mRNA.
Conclusion
In conclusion, in this relatively large bladder cancer case-
control study, a marginal association with bladder cancer
risk was found for the MRE11 SNP rs2155209. Associa-
tions between bladder cancer risk and both smoking and
dye exposure were confirmed. Results of this study need
validation in another case-control cohort and a larger
population is required to fully investigate possible inter-
actions of variants with smoking and dye exposure.
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